Akebia Therapeutics - Voice Trial Meets Stopping Criteria With Win Odds Of 1.16 As Of June 1, 2026

Akebia Therapeutics Inc NASDAQ:AKBA:

• AKEBIA THERAPEUTICS - VOICE TRIAL MEETS STOPPING CRITERIA WITH WIN ODDS OF 1.16 AS OF JUNE 1, 2026

• AKEBIA THERAPEUTICS - NO SIGNIFICANT DIFFERENCE IN MORTALITY: VAFSEO 8.77% VERSUS ESA 8.78% PER 100 PATIENT-YEARS

• AKEBIA THERAPEUTICS - USRC KIDNEY RESEARCH STOPS VOICE TRIAL AFTER INTERIM ANALYSIS SHOWS IMPROVED SAFETY WITH VAFSEO